1445853-63-3

Upstream product

• 1445854-23-8 ethyl 2-(4-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)-2-(hydroxymethyl)phenoxy)acetate 
• 1445854-22-7 4-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)-pentan-3-yl)-2-(hydroxymethyl)phenol 
• 1445854-21-6 methyl 2-hydroxy-5-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)benzoate 
• 1445854-20-5 methyl 2-(benzyloxy)-5-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)benzoate 
• 1445854-19-2 methyl 2-(benzyloxy)-5-(3-(4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl)pentan-3-yl)benzoate 
• 1445854-18-1 methyl 2-(benzyloxy)-5-(3-(4-hydroxy-3-methylphenyl)-pentan-3-yl)benzoate 
• 1445854-17-0 4-(3-(4-(benzyloxy)-3-bromophenyl)pentan-3-yl )-2-methylphenol 
• 1445854-16-9 3-(4-(benzyloxy)-3-bromophenyl)pentan-3-ol 
• 176240-84-9 methyl 4-(benzyloxy)-3-bromobenzoate 

Relevant academic research and scientific papers

BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER

The present disclosure relates to novel bis-(aryl/heteroaryl)-methylene compounds of formula (I) having vitamin D receptor agonist and histone deacetylase (HDAC) inhibitory efficacy as well as to methods for reducing or inhibiting the proliferation of can